Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 10/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.43 |
| ▸ | MTOR | P42345 | 10/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063482 | 0.82 | MTOR (0.44) | PIK3R1PIK3CAMTORCNR2 | |
| SCHEMBL4064302 | 0.80 | PDGFRB (0.47) | — | |
| SCHEMBL4071736 | 0.79 | GAK (0.51) | MTORSTAT3 | |
| SCHEMBL4063407 | 0.77 | TLR9 (0.45) | — | |
| SCHEMBL8196991 | 0.77 | ADORA1 (0.42) | — | |
| SCHEMBL7497665 | 0.77 | ADORA1 (0.42) | GAA | |
| SCHEMBL4127690 | 0.74 | SMN1; SMN2 (0.48) | PIK3CAMTOR | |
| SCHEMBL4069356 | 0.73 | ALDH1A1 (0.36) | CNR2 | |
| SCHEMBL4064298 | 0.71 | ABL1 (0.41) | — | |
| SCHEMBL4068711 | 0.71 | ADORA1 (0.37) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851217-B1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2009-02-11 | — | — | EP | claimed |
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | 4 AZA BIOSCIENCE NV (BE) | 2008-12-18 | — | — | US | claimed |
| EP-1851217-B1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2009-02-11 | — | — | EP | disclosed |
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | 4 AZA BIOSCIENCE NV (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | PNPO, TPMT, TNF | PIK3R1 2935/4885PIK3CA 1151/4885MTOR 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.